UNITED THERAPEUTICS Corp (UTHR)
- Sector
- Biotechnology
- Last price
- $586.48
- As of
Kresmion compiles this page from UTHR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
UNITED THERAPEUTICS Corp (UTHR): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-22.
See the full UTHR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for UTHR on one page. Preview it with sample data, then open it live with a free account.
Preview the UTHR dossierActive events for UTHR
- highInsider cluster: sales
2 insiders at UTHR sold $25.2M this week
- highInsider cluster: sales
2 insiders at UTHR sold $20.0M this week
- highInsider cluster: sales
2 insiders at UTHR sold $25.1M this week
- highInsider cluster: sales
2 insiders at UTHR sold $19.9M this week
- highInsider cluster: sales
2 insiders at UTHR sold $25.3M this week
FREE, NO ACCOUNT
Every event on UTHR, as it fires
You are seeing 5 of 20 events recorded on UTHR since 2026-05-31.
The five above landed across 3 days. The other 15 were recorded on 6 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in UTHR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 91307C102 · 2026Q2 | $925.8M | 1.27% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 91307C102 · 2026Q2 | $221.6M | 0.08% | , |
| CITADEL ADVISORS LLCCUSIP 91307C102 · 2026Q2 | $165.1M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 91307C102 · 2026Q2 | $109M | 0.12% | , |
| Bridgewater Associates, LPCUSIP 91307C102 · 2026Q2 | $60.3M | 0.25% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 91307C102 · 2026Q2 | $6.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, UTHR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
UTHR against its peers
UTHR's operating margin of 46.9% ranks in the 88th percentile of 19 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | UTHR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 3.2B USD | 2.3B USD | 68 | 19 |
| Gross margin | 87.9% | 85.2% | 63 | 14 |
| Operating margin | 46.9% | 8.4% | 88 | 19 |
| Net margin | 41.9% | 6.9% | 93 | 20 |
| Return on equity | 18.8% | 6.2% | 79 | 20 |
| P / E | 21.1x | 31.1x | 17 | 8 |
Peers (23): INCY, ROIV, BNTX, RPRX, INSM, ALNY, GMAB, BIIB, EXEL, ASND, RVMD, ONC, NBIX, HALO, BBIO, SMMT, ARGX, BMRN, NTRA, APGE.D, KYMR, CAI, MDGL. Left out: IVBXF (no annual filing), SBMFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (UTHR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow UTHR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to UTHR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.